ASH 2018 | Generic vs. branded imatinib for CP-CML: a multicenter, observational study
Branded imatinib was the first tyrosine kinase inhibitor (TKI) approved for chronic myeloid leukemia (CML) treatment. Generic formulations now available have since been used as a more cost-effective treatment, but there are few studies that have evaluated its efficacy and safety. Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, presents the exciting results from a multicenter, observational study that evaluated the efficacy and safety of generic vs. branded imatinib as a first-line treatment for chronic phase (CP)-CML. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up